Upjohn's Depo-Provera for contraception
FDA's Fertility and Maternal Health Drugs Advisory Committee will meet June 19 to discuss the company's supplemental NDA, filed April 30, for the use of injectable medroxyprogesterone acetate suspension for contraception. Upjohn originally had filed for the contraceptive indication in 1967, but withdrew the application in 1986 in order to resubmit it with new safety data. The drug is indicated for adjunctive therapy and palliative treatment of inoperable, recurrent and metastatic endometrial carcinoma or renal carcinoma. The meeting begins at 9 a.m. in FDA's Parklawn Building in Rockville, Maryland.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.
The Senate Health, Education, Labor and Pensions Committee voted to advance Monarez's nomination to lead the CDC as the agency announced the largest US measles outbreak in 22 years.
The Pediatric Advisory Committee supported routine safety monitoring for three vaccines and 21 drugs, but the panel’s consumer representative said adverse event reporting needs improvement and FDA literature reviews should include lawsuits as well as social media.